In vitro assessment of antiborrelial activity of OspA vaccine sera.
Prevention of Lyme disease by the recombinant OspA-based vaccine reportedly works by preventing transmission of spirochetes from ticks to humans. We report on an in vitro microculture assay, which can be used to provide an indicator of the need for booster doses of vaccine.
Fawcett
Paul T
PT
Immunology Laboratory, Department of Research, A. I. duPont Hospital for Children, Wilmington, Delaware 19803, USA. pfawcett@nemours.org
Rose
Carlos D
CD
Gibney
Kathleen M
KM
D000954:Antigens, Surface / Q000008:administration & dosage*; D001425:Bacterial Outer Membrane Proteins / Q000008:administration & dosage*; D001428:Bacterial Vaccines; D025065:Borrelia burgdorferi / Q000187:drug effects* / Q000254:growth & development / Q000276:immunology; D004797:Enzyme-Linked Immunosorbent Assay; D006801:Humans; D007106:Immune Sera / Q000276:immunology*; D008074:Lipoproteins; D011237:Predictive Value of Tests; D012698:Serologic Tests / Q000592:standards; D014611:Vaccination / Q000592:standards; D014775:Virus Activation / Q000276:immunology
D000954:Antigens, Surface; D001425:Bacterial Outer Membrane Proteins; D001428:Bacterial Vaccines; D007106:Immune Sera; D008074:Lipoproteins; C072045:OspA protein